{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    5,
    7,
    54,
    55,
    57,
    58,
    59
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_6.0",
        "affectedSection": "Sections 1.2.2.2, 5.1.2, 5.1.4, 5.1.5.2.1, 5.1.5.3.2, and Appendix 11",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Terminology update to align with Investigator's Brochure Version 15."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_6.0",
        "affectedSection": "Sections 5.1.2, 5.1.4.1, 5.2.3, and Appendix 11",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Replacement of systemic immune activation with specific conditions (HLH/MAS) and removal from AESI list."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_6.0",
        "affectedSection": "Appendix 1",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removal of redundant PK/ADA sampling during Follow-Up."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_6.0",
        "affectedSection": "Appendix 11",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Update to myocarditis signs/symptoms and inclusion of CRS management guidelines."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_6.0",
        "reasonText": "To align with the Atezolizumab Investigator's Brochure, Version 15 regarding risks and management guidelines.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_6.0",
        "reasonText": "To address a request by the French National Agency for the Safety of Medicines and Health Products (ANSM).",
        "category": "Regulatory",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_6.0",
        "reasonText": "Assessment was already discontinued as of Version 3; removal for consistency.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_6.0",
        "reasonText": "To align with recent publication (Lee et al. 2019) regarding cytokine-release syndrome definition and management.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_6.0",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Multiple",
        "beforeText": "immune-related",
        "afterText": "immune-mediated",
        "summary": "Updated terminology for events associated with atezolizumab."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_6.0",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.1.2",
        "beforeText": "systemic immune activation",
        "afterText": "hemophagocytic lymphohistiocytosis and macrophage activation syndrome",
        "summary": "Replaced systemic immune activation with specific potential risks."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_6.0",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "5.1.4.1",
        "beforeText": "Management guidelines for systemic immune activation",
        "afterText": "null",
        "summary": "Deleted section and renumbered subsequent sections."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_6.0",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "5.2.3",
        "beforeText": "systemic immune activation (as an AESI)",
        "afterText": "null",
        "summary": "Removed systemic immune activation from the list of adverse events of special interest."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_6.0",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "Appendix 11",
        "beforeText": "null",
        "afterText": "laboratory (e.g., B-type natriuretic peptide) and cardiac imaging abnormalities",
        "summary": "Added specific signs/symptoms suggestive of myocarditis."
      },
      {
        "id": "change_6",
        "amendmentId": "amend_6.0",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "Appendix 11",
        "beforeText": "null",
        "afterText": "guidelines for cytokine-release syndrome (CRS)",
        "summary": "Included CRS management within infusion-related reaction guidelines."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 4,
      "changeCount": 6
    }
  }
}